Affiliate disclosure: This article contains affiliate links. If you buy through them, we may earn a commission at no extra cost to you. This does not influence our assessment of the evidence below.
Evidence rating: Moderate for urinary tract health, but essentially absent for bladder leakage — the two are not the same thing
What FemiPro Claims To Be
FemiPro is a women’s capsule marketed around bladder control and “pee leaks,” with a secondary story about balancing the urinary microbiome. It pairs a cranberry-and-herb blend with five Lactobacillus strains.
The ingredient list is better than the marketing. This is a genuinely reasonable urinary-tract-health formula wearing an incontinence label, and the gap between those two things is the most useful thing a review can tell you.
What’s Actually In It
Unusually for this category, FemiPro publishes a real Supplement Facts panel:
UTI Herbal Blend — 350 mg per serving
- Mimosa pudica seed extract
- Cranberry extract (Vaccinium macrocarpon), standardized to 30% proanthocyanidin
- Bearberry (Arctostaphylos uva-ursi) leaf
- Berberine HCl extract, 8%
Probiotic Blend — 50 mg per serving
- Lactobacillus crispatus LCr86
- Lactobacillus acidophilus LA88
- Lactobacillus plantarum N13
- Lactobacillus gasseri LG08
- Lactobacillus casei LC16
Both blends are proprietary, so per-ingredient amounts aren’t broken out. That matters arithmetically: 350 mg split four ways can’t give you a clinical-strength dose of cranberry PACs and meaningful uva ursi and meaningful berberine. Something is present at a token amount. The 50 mg probiotic blend likewise sits well below what most probiotic trials deliver.
What The Research Shows
According to PubMed, the cranberry and Lactobacillus components have real supporting literature — for infection recurrence, which is a different outcome from leakage.
Cranberry reduces the risk of recurrent UTI by about a quarter. A systematic review and meta-analysis pooled 7 randomized controlled trials in 1,498 otherwise healthy women with a history of UTI. Cranberry reduced UTI risk by 26% (pooled risk ratio 0.74). The authors were measured about it: heterogeneity was 54%, two studies had high loss to follow-up or selective reporting, and only two enrolled more than 300 people. Their conclusion asked for larger, higher-quality trials before treating it as settled. DOI
The L. crispatus evidence is real — but it was delivered vaginally, not swallowed. In a randomized, double-blind, placebo-controlled phase 2 trial, 100 premenopausal women with recurrent UTI received either an L. crispatus intravaginal suppository or placebo. Recurrence occurred in 15% on the probiotic versus 27% on placebo (relative risk 0.5), and among women who maintained high vaginal colonization, the reduction was large and statistically significant. Note the route of administration: this is a suppository trial, and FemiPro is a capsule you swallow. DOI
And a systematic review of that whole approach found the picture unresolved. Eight studies of vaginal Lactobacillus suppositories for recurrent UTI prevention were reviewed. Five of the seven that measured recurrence found a lower incidence with probiotics — but only two reached statistical significance, and both of those were non-randomized. The reviewers’ verdict: safe, yes; effective, “inconclusive,” with appropriate dose and duration still unknown. DOI
Bearberry has a trial, and it’s a cautionary one. A double-blind randomized controlled trial across 42 German family practices gave 398 women with uncomplicated UTI either uva ursi extract or single-dose fosfomycin. Uva ursi cut antibiotic use by 63.6% — the headline result — but it failed the non-inferiority test on symptoms, with a 36.5% higher symptom burden than the antibiotic arm. Eight women in the uva ursi group developed pyelonephritis versus two on fosfomycin. This is an ingredient with an established safety ceiling (it is generally not recommended for long-term or repeated use), and this trial is a reason to take that seriously. DOI
The claim with no evidence behind it is the one on the label. None of the research above studied urinary incontinence, urgency, or leakage. Preventing bacterial infection and controlling bladder muscle function are separate physiological problems, and there is nothing in this ingredient list with trial evidence for the second one. Pelvic floor training and medical evaluation are what the evidence actually supports for leakage.
The Honest Verdict
What holds up: Cranberry proanthocyanidins have a defensible meta-analysis behind them for reducing recurrent UTI risk in women, and the anti-adhesion mechanism is well-described. L. crispatus is the correct organism to be interested in — it’s the dominant protective species in a healthy vaginal microbiome, and depletion of it tracks with UTI risk. Berberine has broad antimicrobial activity. Publishing an actual Supplement Facts panel with a named cranberry standardization deserves credit; most competitors don’t.
What doesn’t: Three things. First, the leakage claim is unsupported by the ingredients. Second, the route mismatch — the strongest L. crispatus result came from a vaginal suppository, and an oral capsule is not the same intervention. Third, the math: a 350 mg four-way blend cannot deliver clinical doses of everything in it, and the uva ursi that’s in there carries a trial showing worse symptom control and more kidney infections than an antibiotic, plus a well-known caution against prolonged use.
Who this makes sense for: A woman with a history of recurrent urinary tract infections, already working with her doctor, who wants a cranberry-and-Lactobacillus product and understands she’s buying risk reduction at the margins. If that’s the goal, check the actual proanthocyanidin milligrams — that number is what the research runs on.
Who should skip it: Anyone whose actual problem is leakage or urgency; the evidence points you toward pelvic floor physiotherapy and a urogynecologist, not this bottle. Also anyone pregnant or breastfeeding (uva ursi and berberine are both contraindicated), anyone on medications metabolized by CYP enzymes (berberine has real interaction potential), anyone planning to take it continuously for months, and anyone with active UTI symptoms — burning, fever, back pain — which need antibiotics and a clinician, promptly.
Check current pricing and availability
View FemiPro on the official site
This article is for informational purposes only and is not medical advice. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration. Talk to your physician before starting any supplement, especially if you are pregnant, have a diagnosed condition, or take medication.
Research cited via PubMed: